GLUE vs ARVN vs KYMR vs PRAX vs VRTX vs KO

For growth investors, Monte Rosa Therapeutics, Inc.

(GLUE) is the stronger pick with 63. 5% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). The Coca-Cola Company (KO) offers the better valuation at 27. 1x trailing P/E (25. 2x forward), making it the more compelling value choice. Analysts rate Monte Rosa Therapeutics, Inc. (GLUE) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, The Coca-Cola Company (KO) is the cheapest at 27.

1x versus Vertex Pharmaceuticals Incorporated at 29. 0x. On forward P/E, Vertex Pharmaceuticals Incorporated is actually cheaper at 23. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: The Coca-Cola Company wins at 2. 26x versus Vertex Pharmaceuticals Incorporated's 2. 78x.

Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +130.

6%, compared to -91. 3% for Arvinas, Inc. (ARVN). Over 10 years, the gap is even starker: VRTX returned +391. 5% versus ARVN's -55. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

15β versus Praxis Precision Medicines, Inc. 's 1. 55β — meaning PRAX is approximately -1145% more volatile than KO relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Monte Rosa Therapeutics, Inc.

(GLUE) is pulling ahead at 63. 5% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Vertex Pharmaceuticals Incorporated grew EPS 836. 5% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, ARVN leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.

7% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 32. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39. 4% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, The Coca-Cola Company (KO) is the more undervalued stock at a PEG of 2. 26x versus Vertex Pharmaceuticals Incorporated's 2. 78x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Vertex Pharmaceuticals Incorporated (VRTX) trades at 23. 1x forward P/E versus 25. 2x for The Coca-Cola Company — 2. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRAX: 140. 3% to $595. 93.

In this comparison, KO (2.

5% yield) pays a dividend. GLUE, ARVN, KYMR, PRAX, VRTX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

15), 2. 5% yield, +120. 9% 10Y return). Praxis Precision Medicines, Inc. (PRAX) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +120. 9%, PRAX: -40. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (GLUE (Healthcare) and ARVN (Healthcare) and KYMR (Healthcare) and PRAX (Healthcare) and VRTX (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: GLUE is a small-cap high-growth stock; ARVN is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; VRTX is a mid-cap quality compounder stock; KO is a large-cap quality compounder stock. KO pays a dividend while GLUE, ARVN, KYMR, PRAX, VRTX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.